Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial.
Sarang Kim, Marnie Bertolet, Bernard R Chaitman et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial from the MINT study evaluated the incidence of recurrent myocardial infarction (MI) in 3,504 patients with acute MI and anemia through centralized troponin review. It found that 7.8% experienced recurrent MI within 30 days, with 56.7% identified only by central review. Patients with centrally identified MI had a significantly increased risk of cardiac death at 30 days (RR 1.9) and 180 days (RR 1.7).
Key findings
- 7.8% of patients had a recurrent MI within 30 days.
- 56.7% of recurrent MIs were identified only through centralized troponin review.
- Patients with centrally identified MI had a 1.9 times higher risk of cardiac death at 30 days.
- Cardiac death risk was 1.7 times higher at 180 days for those with centrally identified MI.
Why it matters
The study highlights the importance of centralized troponin review in identifying recurrent MIs, which may otherwise go unnoticed. Understanding the prognosis associated with these events can inform clinical decision-making and patient management strategies.